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Abstract: QT interval prolongation is associated with torsade de pointes and sudden cardiac death.
QT prolongation can be caused by many drugs that are commonly prescribed in elderly residential
aged care populations. The aim of this study was to investigate the prevalence of use of QT-prolonging
drugs and to identify interventions made by pharmacists to reduce the risk of QT prolongation
when conducting medication reviews in aged care. A retrospective analysis of 400 medication
reviews undertaken by Australian pharmacists in aged care settings was conducted. The assessment
included the risk of QT prolongation due to prescribed medications and other risk factors and the
recommendations made by pharmacists to reduce the risk of QT prolongation. There was a high
prevalence of the use of QT-prolonging medication, with 23% of residents (92 out of 400) taking
at least one medication with a known risk of QT prolongation. Amongst the 945 prescribed drugs
with any risk of QT prolongation, antipsychotics were the most common (n = 246, 26%), followed
by antidepressants (19%) and proton pump inhibitors (13%). There appeared to be low awareness
amongst the pharmacists regarding the risk of QT prolongation with drugs. Out of 400 reviews,
66 residents were categorised as high risk and were taking at least one medication associated with QT
prolongation; yet pharmacists intervened in only six instances (9%), mostly when two QT-prolonging
medications were prescribed. There is a need to increase awareness amongst pharmacists conducting
medication reviews regarding the risk factors associated with QT prolongation, and further education
is generally needed in this area.
Keywords: QT interval prolongation; torsade de pointes; residential aged care facilities; nursing
homes; pharmacist; medication review; elderly
1. Introduction
The QT interval is defined as the time between the onset of the QRS complex and the offset of the
T wave, as seen on the surface electrocardiogram (ECG), and represents ventricular depolarisation and
repolarisation, i.e., the time between contraction and relaxation of the heart muscle [1]. The QT interval
in healthy adult males and females is typically <430 msec and <450 msec, respectively [2]. A prolonged
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QT interval (>450 msec for males and >470 msec for females) is associated with an increased risk of
ventricular arrhythmias, including the potentially lethal torsade de pointes (TdP) [2].
TdP is a rare polymorphic ventricular arrhythmia that typically occurs in self-limiting bursts
leading to symptoms of dizziness, palpitations, syncope, and seizures, but can occasionally progress
to ventricular fibrillation and sudden cardiac death [3]. The electrocardiographic waveform of
TdP is characterised by rapid irregular QRS complexes that appear to twist around the isoelectric
baseline. It can result from having inherited long QT syndrome (LQTS) or acquired conditions such as
drug-induced QT prolongation [4]. The latter observation led Link and colleagues to note that “one of
the most feared complications in medicine is sudden death caused by drug-induced proarrhythmia” [5].
Many medications commonly prescribed in residential aged care populations may prolong the QT
interval directly or indirectly. These include antipsychotics, antidepressants, and medications for
cardiac conditions [6].
The QT interval can also be impacted by many clinical conditions, such as thyroid disturbances,
diseases of the cardiovascular system (e.g., hypertension, atrial fibrillation, bradycardia and conduction
disease, structural heart disease, heart failure, and ischaemic cardiomyopathy), hypokalaemia,
hypocalcaemia, hypochloraemia, and hypomagnesaemia, neurological and metabolic disturbances,
and renal and liver impairment [7–10]. Apart from genetic factors, patient demographics such as older
age (≥65 years) and female gender are also risk factors for QT prolongation [10].
In residential aged care facilities, patients with multiple risk factors for QT prolongation, including
the use of QT-prolonging drugs, are common [6]. Therefore, pharmacists working in the aged care
sector can play a pivotal role in the recognition of high-risk patients and management of drugs
associated with QT prolongation.
In Australia, residential medication management reviews (RMMRs) are the primary service for
promoting the quality use of medicines in aged care [11–13]. Collaborative RMMRs are defined
as “resident-focused, collaborative, comprehensive medication reviews involving the systematic
evaluation of the resident’s complete medication regimen and management of that medicine in the
context of other relevant clinical information and the resident’s health status” [13]. RMMRs are
provided by accredited pharmacists and may include participation from general medical practitioners,
aged care nursing staff, and residents and their family members; they have been remunerated since
1997. In general, only one RMMR can be performed annually for each resident. To be eligible to
receive government reimbursement for undertaking medication reviews, pharmacists must achieve
and maintain a qualification additional to their license to practice. Pharmacists must be accredited
with either of two bodies responsible for training and assessing accredited pharmacists (Australian
Association of Consultant Pharmacy or the Society of Hospital Pharmacists of Australia). To obtain
accreditation with either body, a pharmacist must be registered to practice as a pharmacist in
Australia and successfully complete a variety of competency-based assessments. When performing
medication reviews, the accredited pharmacists are not required to conduct standardised checks
(e.g., for medications using explicit criteria for inappropriate prescribing or electronic tools to detect
potential drug–drug interactions). The procedure varies amongst individual pharmacists, and the
ability to detect potential drug-related problems is inevitably dependent on the individual’s knowledge
and experience.
An earlier publication from our research group [14] addressed the identification of community-
dwelling patients at risk of QT interval prolongation during medication reviews, and concluded that
there is a need to improve knowledge and awareness of this topic amongst pharmacists performing
such medication reviews. This complementary research explored the role of pharmacists in reducing
the risk of QT prolongation in residential aged care patients by conducting medication reviews. The aim
was to investigate the prevalence of the use of QT-prolonging drugs in residential aged care facility
residents and to identify the interventions made by pharmacists to reduce the risk of QT prolongation
when conducting RMMRs.
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2. Materials and Methods
A sample of 1000 de-identified RMMR reports was obtained from a clinical pharmacy service
provider. The reports were performed by nine accredited pharmacists during the period of
2013–2015. We randomly selected (using computer-generated random numbers) and analysed
400 of these reports retrospectively. Data including patient demographics, clinical and medication
information, and the pharmacists’ recommendations were extracted and entered into a spreadsheet.
In particular, the researchers could determine clinical risk factors for QT prolongation and the use of
QT-prolonging medications.
The website Crediblemeds.org [15] was used by the researchers for a list of drugs that are
associated with an increased risk of QT prolongation. A scientific review board, based on ongoing and
systematic analysis of evidence, categorised drugs into three categories based on their ability to cause
QT prolongation or TdP [14]. These categories are (1) known risk of TdP—drugs that prolong the
QT interval and are clearly associated with a known risk of TdP, even when taken as recommended;
(2) possible risk of TdP—drugs that can cause QT prolongation but currently lack evidence for a risk of
TdP when taken as recommended; and (3) conditional risk of TdP—drugs that are associated with
TdP but only under certain conditions or by creating conditions that facilitate or induce TdP [14].
The website also has a fourth category, drugs that should be avoided in individuals with congenital
long QT syndrome; however, this category was not included in the study.
The RISQ-PATH score is a validated tool used to predict the risk of QT prolongation [16]. It has
two elements and is calculated by the sum of (1) identified risk factors based on evidence, with points
allocated on the strength of that evidence; and (2) QT-prolonging drugs, with each being allocated
points based on the associated risk. A RISQ-PATH score of <10 was considered a low risk of QT
prolongation whilst a RISQ-PATH score of ≥10 was considered a high risk [16]. Table 1 shows the
associated risk factors and allocated points in accordance with the RISQ-PATH score. It should be
noted that some risk factors were not included in the overall RISQ-PATH score due to lack of available
or consistently reported data (i.e., smoking status, body mass index, and prolonged QT interval at
baseline ECG).
Table 1. Risk factors for QT prolongation according to RISQ-PATH score [15].
Risk Factor Points Allocated
Age ≥65 years 3
Female gender 3
Smoking 3
Body mass index ≥30 kg/m2 1
Ischaemic cardiomyopathy 3
Hypertension 3
Arrhythmia 3
Prolonged QT interval on baseline ECG 6
Thyroid disturbance 3
Liver failure 1
Neurological disorder (stroke, trauma, infection, tumour) 0.5
Diabetes 0.5
Hypokalaemia (potassium ≤3.5 mmol/L) 6
Hypocalcaemia (calcium <2.15 mmol/L) 3
CRP >5mg/L (inflammation) 1
Renal impairment (eGFR ≤30 mL/min/1.73 m2) 0.5
For each known risk category 1 drug 3
For each possible risk category 2 drug 0.5
For each conditional risk category 3 drug 0.25
Total RISQ-PATH score Max 40.5 + sum QT drugs
CRP, C-reactive protein; ECG, electrocardiogram.
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3. Results
The characteristics of the 400 patients are presented in Table 2 and the most commonly prescribed
QT-prolonging medications are shown in Table 3. Overall, 92% (369/400) of residents were taking at
least one medication associated with a risk of QT prolongation (i.e., known, possible, or potential
risk). There were 92 (23%) residents taking at least one drug with known risk of QT prolongation.
The most commonly prescribed drugs with a known risk of QT prolongation in this sample of aged care
residents were antidepressants (escitalopram and citalopram) (n = 42 residents, 10%), donepezil (n = 19
residents, 5%), and haloperidol (n = 18 residents, 5%). The most commonly prescribed combinations of
drugs that are associated with a risk of QT prolongation, with at least one drug from the known risk
category, were escitalopram and furosemide (n = 11 residents, 3%), escitalopram and risperidone (n = 8
residents, 2%), and donepezil and furosemide (n = 5 residents, 1%). Amongst the 945 prescribed drugs
with any risk of QT prolongation, antipsychotics were the most common (n = 246, 26%), followed by
antidepressants (19%), and proton pump inhibitors (PPIs; 13%).
Table 2. Patient characteristics.
Characteristics Mean ± SD (Range) or n (%)
Number of residents 400
Age, years 79 ± 13 (37–101)
Female 233 (58%)
Number of medications per resident
Number of medications with known risk of QT prolongation per resident
Number of medications with possible risk of QT prolongation per resident
Number of medications with conditional risk of QT prolongation per resident
12 ± 4 (0–26)
0.2 ± 0.5 (0–2)
1 ± 0.8 (0–4)
1 ± 1.1 (0–5)
Number of medical conditions per resident 10 ± 4 (1–26)
Mean RISQ-PATH score per resident 9.5 ± 4 (0–25.75)
SD, standard deviation.
Age ≥65 years was the most prevalent non-pharmacological risk factor for QT prolongation.
The prevalence of other risk factors is shown in Figure 1. Forty-eight percent (n = 193) of residents had
a high risk of QT prolongation (RISQ-PATH score of ≥10), of whom 77% (n = 149) were female.
Analysing the recommendations of pharmacists in RMMR reports showed that QT prolongation
was only directly identified as an issue of concern a total of 17 times across the 400 residents, 8 of
which were in high-risk patients and 9 in low-risk patients. The majority of the high-risk patients (66%
(n = 127 out of 193)) were not taking any drugs from the known-risk category; rather, they were taking
a combination of possible- and conditional-risk drugs.
More pertinently, 16% (n = 66 out of 400) of the study sample were taking at least one drug with a
known risk of QT prolongation and had a RISQ-PATH score of ≥10. Hence, there were potentially
66 instances where a pharmacist intervention could have been made. Pharmacists identified the
risk of QT prolongation in only 9% (n = 6) of these cases. In these instances, pharmacists made
specific recommendations of a dose reduction in 33.3% (n = 2) of cases, unspecific recommendations of
assess/monitor/review in 33.3% (n = 2) of cases, and no recommendation at all in 33.3% (n = 2) of cases.
Thirty-four percent (n = 23 out of 66) of these high-risk residents were taking one drug from
the known-risk category and had a RISQ-PATH score of ≥15; in all those residents, pharmacists did
not identify the risk of QT prolongation. However, five residents with a RISQ-PATH score of ≥10
were taking two drugs from the known-risk category (amiodarone and escitalopram, citalopram
and haloperidol, domperidone and citalopram), and thus were considered at highest risk of QT
prolongation in the study sample. In those residents, pharmacists identified the risk of drug-induced
QT prolongation in 40% (n = 2 out of 5) of the medication reviews.
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Table 3. Use of QT-prolonging medications.
“Known Risk” Number ofResidents
% of Total
Number of
Medications
“Possible Risk” Number ofResidents
% of Total
Number of
Medications
“Conditional
Risk”
Number of
Residents
% of Total
Number of
Medications
escitalopram 21 2.2 risperidone 73 7.7 furosemide 108 11.4
citalopram 21 2.2 mirtazapine 65 6.9 metoclopramide 92 9.7
donepezil 19 2.0 buprenorphine 46 4.9 quetiapine 71 7.5
haloperidol 18 1.9 memantine 25 2.6 esomeprazole 61 6.5
amiodarone 6 0.6 tramadol 23 2.4 olanzapine 56 5.9
domperidone 4 0.4 venlafaxine 16 1.7 pantoprazole 34 3.6
ondansetron 2 0.2 aripiprazole 12 1.3 sertraline 30 3.2
sotalol 2 0.2 lithium 11 1.2 omeprazole 26 2.8
fingolimod 1 0.1 clozapine 8 0.8 loperamide 22 2.3
flecainide 1 0.1 promethazine 4 0.4 paroxetine 11 1.2
ketoconazole 1 0.1 imipramine 1 0.1 galantamine 11 1.2
TOTAL 96 10 paliperidone 1 0.1 hydrochlorothiazide 10 1.1
tamoxifen 1 0.1 amitriptyline 9 1.0
tetrabenazine 1 0.1 indapamide 7 0.7
tolterodine 1 0.1 amisulpride 4 0.4
TOTAL 288 30 solifenacin 3 0.3
amantidine 2 0.2
fluoxetine 1 0.1
hydroxychloroquine 1 0.1
metronidazole 1 0.1
lansoprazole 1 0.1
TOTAL 561 59
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4. Discussion
Overall, 16% of the sample were at a high risk f QT prolongation and were taking at least
one medication with a nown ri k of QT prolongation. Citalopram and escitalopram were the most
commonly prescribed drugs with a known risk of QT prolongati n. Antipsych tics, ntidepr ssants,
and PPIs were the m st commonly prescribed d ug g oups with any risk of QT prolongation in
this sample.
Polypharmacy in elderly populations is well establish d and increases th risk of adverse
drug rea tions (ADRs). Pharmacist involvement and intervention is key to reducing drug-related
misadventure nd to optimising patient car [17]. Inappropriate use and overuse of drugs uch as
antipsychotics, antidepressants, and PPIs in older adults—especially aged are residents—h ve been
reported in many studies [18–20]. However, research specifically looking t the risk of QT prolong tion
in residents in residential aged care facilities has been lacking.
The large number of QT-prolonging drugs that are prescribed to resi ents in aged care facilities,
combined with the prevalence of risk factors, such as age ≥65 years, diseases of the cardiovascular
system, neurolo ical disturbances, age-related renal decline, and electrolyte imbalances, suggests that
these residents are at a much higher risk of QT prolongation. D spite this, relatively few interventions
were recommended by ph rmacists, and related recommenda ions wer mainly targeted at rugs
with kn wn risk of QT prolonga i n—especially n cases when two drugs with known risk of QT
prolongation were concomitantly used, rather than patients’ other risk factors.
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Most prescribers commonly encounter warnings about drugs that can cause QT prolongation.
However, it may be challenging for clinicians to weigh the potential risk of QT prolongation against
the benefit of a drug [21]. It is particularly difficult for a pharmacist to recommend the removal of a
therapy that appears to be effective and may be considered important for the ongoing management of
the patient (e.g., donepezil in early stage dementia). An observational study in Belgian community
pharmacies reported that when pharmacists contacted prescribers regarding QT-prolonging drug
interactions and proposed interventions, in more than half of the cases the proposed interventions
were considered unnecessary by the prescribers [22].
Our study adds to a growing body of research showing that there is a need for greater awareness
amongst pharmacists and other health professionals regarding the risk factors—both pharmacological
and non-pharmacological—associated with QT prolongation, and hence identification of patients at
greatest risk of TdP [23–25]. Several educational review papers are now available and suitable for this
purpose [4,26–28].
With regard to educational activities providing a greater awareness amongst multiple healthcare
professions about the risk factors associated with QT prolongation, Turner [29] published an editorial
in 2018 entitled: “Proposed proarrhythmic cardiac safety education in medical, pharmacy, and nursing
schools: An interprofessional model.” While teaching students and practitioners of each of these
disciplines about drug-induced QT prolongation and proarrhythmic cardiac safety is a very worthwhile
goal, an interprofessional model takes educational endeavours to an even higher level. The safe
practice of pharmaceutical medicine involves participation of all of these disciplines. Physicians who
are considering prescribing a QT-prolonging medicine need to make a careful analysis of the patient’s
other risk factors for drug-induced prolongation. Second, given their expert knowledge of clinical
pharmacology, pharmacists are well-placed to work closely with physicians as influential arbiters of
sound prescribing decisions, and to alert physicians to injudicious prescribing decisions (although
it will be important to educate prescribing physicians in the value of such work by pharmacists).
Third, nurses in inpatient and residential care settings are well-placed to conduct a final check before a
prescribed and dispensed medicine is administered to a patient [29]. Additionally, Klotzbaugh and
colleagues [28] expanded this line of thinking to include physician assistants. Collectively, these papers
can be regarded as an initial set of resources for educating multiple healthcare professions about
proarrhythmic safety in an interprofessional manner.
The practical use of such resources could occur in several settings. For example, in academic
institutions that have more than one healthcare professional school, joint workshops and/or symposia
provide the opportunity for initial didactic teaching followed by interprofessional discussions involving
students and faculty from each professional school on campus. The papers by Thind and colleagues [27]
and Klotzbaugh [28] may be particularly useful for generating such interprofessional discussions, as they
include clinical vignettes specifically designed for this purpose. Each of the vignettes addresses how
an individual patient was prescribed certain drug(s), and highlights the effects of these prescriptions.
Expert commentary is provided to illustrate “lessons learned” that are valuable to all healthcare
professions addressed here.
A second practical implementation of published resources is the education of professionals
already in clinical practice; continuing education initiatives in proarrhythmic cardiac safety can be very
valuable. One example, a paper by Turner and colleagues [4], is being used for continuing education in
medicine and pharmacy, and it is hoped that such activities will also be created for the nursing and
physician assistant professions.
There are limitations to this study. The data available in the RMMRs for some of the risk factors
were limited and therefore there were potentially more patients who could have been classified as
being at high risk if all the data were available. We also did not have clinical outcome data for the
residents, such as QT intervals or the incidence of QT prolongation. The existing system and the
risk calculation tool (RISQ-PATH) adopted for this study were largely based on a limited number of
relatively small observational studies that categorized the risk based on the potential of a factor or a
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drug to cause QT prolongation. It is possible that a previous annual medication review addressed QT
prolongation. A relatively small number of accredited pharmacists performed the reviews. Finally,
awareness amongst pharmacists conducting medication reviews regarding the risk factors associated
with QT prolongation may have improved since 2015.
5. Conclusions
It appears that accredited pharmacists in Australia are not routinely evaluating QT prolongation
risk when performing medication reviews in aged care settings, despite residents in aged care facilities
being at an appreciable risk of drug-induced QT prolongation and potentially TdP. There is a need for
greater awareness amongst pharmacists conducting medication reviews regarding drug-induced QT
prolongation and other risk factors associated with QT prolongation.
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